ReviewEuropean respiratory review : an official journal of the European Respiratory Society2020
Short-course systemic corticosteroids in asthma: striking the balance between efficacy and safety.
Review in European respiratory review : an official journal of the European Respiratory Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 4 syntheses or guidelines pooled it, 132 citations in OpenAlex.
- Pooled it
- Metformin use & asthma outcomes in patients with concurrent diabetes & bronchial asthma: A systematic review & meta-analysis.The Indian journal of medical research · 2025 · on this mapPooled it
- Burden of corticosteroid therapy in patients with immunoglobulin A nephropathy (IgAN): a systematic literature review.BMC nephrology · 2025Pooled it
- Pediatric Outpatient Prescriptions in Countries With Advanced Economies in the 21st Century: A Systematic Review.JAMA network open · 2022Pooled it
- Dupilumab in chronic obstructive pulmonary disease: a pooled analysis of emergency department visits, hospital admissions, and systemic corticosteroid use.American journal of respiratory and critical care medicine · 2026Trial
- Real-world two-year outcomes of mepolizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting severe asthma.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Article
- Update on Pediatric asthma management: Recent advances.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2026Review
- Corticosteroid Exposure in Chronic Rhinosinusitis and Global Airway Disease: Adrenal and Bone Impact.The Laryngoscope · 2026Article
- Impact of pre-transplantation exposure to immunosuppressive agents on lung transplant outcomes in interstitial lung disease.Transplant international : official journal of the European Society for Organ Transplantation · 2026Article
- Agreement Between ICD-10 Code-Only and Composite Definitions of Asthma Exacerbations in Electronic Health Records: A Multicenter Cohort Study in Taiwan, 2017-2023.Clinical epidemiology · 2026Article
- Economic burden of asthma multimorbidity in Singapore: Shadow costs of steroid use.The World Allergy Organization journal · 2025Article
- Risk of Moderate to Severe Ocular Surface Disease Associated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A Multicenter Cohort Study.Ophthalmology and therapy · 2025Article
- Biomarker profile and disease burden associated with intermittent and long-term oral corticosteroid use in patients with severe asthma prior to biologic initiation in real-life (STAR).The World Allergy Organization journal · 2025Article
- Treatment trends and risks of corticosteroid use in adult primary immune thrombocytopenia: a claims database study in Japan.International journal of hematology · 2025Article
- A RESPONSE to antiThe journal of allergy and clinical immunology. Global · 2025Article
- Review
- Short Course of Systemic Steroids for Acute Respiratory Diseases During Infancy and Final Adult Height, Weight, and BMI: Preliminary Results from a Prospective Cohort Study.Journal of clinical medicine · 2025Article
- Use of oral corticosteroids in patients with asthma: how far is clinical practice from the guidelines? Results from surveys of patients and doctors.Frontiers in allergy · 2025Article
- Experiences of Oral Corticosteroid Use and Adverse Effects: A National Cross-Sectional Survey of People with Asthma.Patient preference and adherence · 2025Article
- Maintenance oral steroids are not required in severe asthma.ERJ open research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Short courses of systemic corticosteroids (SCS), both oral and injectable, are very effective for the resolution of acute asthma symptoms, including exacerbations. However, the benefits of SCS, even short courses, must be balanced against the impact of their side-effects. While the adverse consequences of long-term use are widely recognised, there appears to be a perception in the medical community that short courses of SCS are safe. Limited but growing evidence in the literature suggests that even very brief dosing periods (3-7 days) of SCS are enough to cause significantly negative outcomes for patients. Short courses of SCS are associated with increased risk of adverse events including loss of bone density, hypertension and gastrointestinal ulcers/bleeds, in addition to serious impacts on mental health. Strategies to improve asthma control are recommended, including: 1) as-needed combination therapies in mild asthma; 2) risk factor reduction; 3) improving adherence/inhaler technique; 4) earlier initiation of add-on therapies; 5) use of biologics in appropriate patients; 6) development of new therapies to better control the disease; and 7) widespread education of the medical community. We propose that patients and primary care physicians should consider a cumulative SCS dose of 1 g per year as a highly relevant and easy-to-recall threshold.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.